1. Market Research
  2. > Healthcare
  3. > Pathology
  4. > Chronic Disease Market Trends
  5. > Idiopathic (Essential) Hypertension Global Clinical Trials Review, H2, 2014

Idiopathic (Essential) Hypertension Global Clinical Trials Review, H2, 2014

  • September 2014
  • -
  • GlobalData
  • -
  • 113 pages

Summary

Table of Contents

Search Inside

Idiopathic (Essential) Hypertension Global Clinical Trials Review, H2, 2014

Summary

GlobalData's clinical trial report, “Idiopathic (Essential) Hypertension Global Clinical Trials Review, H2, 2014" provides data on the Idiopathic (Essential) Hypertension clinical trial scenario. This report provides elemental information and data relating to the clinical trials on Idiopathic (Essential) Hypertension. It includes an overview of the trial numbers and their recruitment status as per the site of trial conduction across the globe. The databook offers a preliminary coverage of disease clinical trials by their phase, trial status, prominence of the sponsors and also provides briefing pertaining to the number of trials for the key drugs for treating Idiopathic (Essential) Hypertension. This report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by GlobalData's team of industry experts.

Note: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- Data on the number of clinical trials conducted in North America, South and Central America, Europe, Middle-East and Africa and Asia-pacific and top five national contributions in each, along with the clinical trial scenario in BRIC nations
- Clinical trial (complete and in progress) data by phase, trial status, subjects recruited and sponsor type
- Listings of discontinued trials (suspended, withdrawn and terminated)

Reasons to buy

- Understand the dynamics of a particular indication in a condensed manner
- Abridged view of the performance of the trials in terms of their status, recruitment, location, sponsor type and many more
- Obtain discontinued trial listing for trials across the globe
- Espy the commercial landscape of the major Universities / Institutes / Hospitals or Companies

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 60 Million searchable statistics with tables, figures & datasets
  • More than 25,000 trusted sources
Get This Report
24/7 Customer Support

Talk to Veronica

+1 718 514 2762

Purchase Reports From Reputable Market Research Publishers
Pulmonary Arterial Hypertension (PAH) - Market Insights, Epidemiology and Market Forecast-2023

Pulmonary Arterial Hypertension (PAH) - Market Insights, Epidemiology and Market Forecast-2023

  • $ 4950
  • Industry report
  • January 2017
  • by Delve Insight

DelveInsight’s Pulmonary Arterial Hypertension (PAH) - Market Insights, Epidemiology and Market Forecast-2023” Reports provides an overview of the disease and global market trends of the Pulmonary ...

Global Anti-hypertensive Drugs Market - Market Share, Trends and Forecasts (2017 - 2022)

Global Anti-hypertensive Drugs Market - Market Share, Trends and Forecasts (2017 - 2022)

  • $ 4250
  • Industry report
  • January 2017
  • by Mordor Intelligence LLP

The Global market for Anti-hypertensive drugs Market is expected to reach $XX by the end of 2020 growing at a CAGR of around XX% from 2015 to 2021. Hypertension is a chronic medical condition where there ...

Pulmonary Arterial Hypertension (PAH) - Epidemiology Forecast To 2023

Pulmonary Arterial Hypertension (PAH) - Epidemiology Forecast To 2023

  • $ 2750
  • Industry report
  • January 2017
  • by Delve Insight

DelveInsight “Pulmonary Arterial Hypertension (PAH) - Epidemiology Forecast To 2023” provides an overview of the epidemiology trends of Pulmonary Arterial Hypertension (PAH) in seven major markets ...


ref:plp2014

Reportlinker.com © Copyright 2017. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.